ArticleCurrent cellular biochemistry
Differential nuclear staining assay for high-throughput screening to identify cytotoxic compounds.
Article in Current cellular biochemistry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 96 citations in OpenAlex.
- Targeting colorectal cancer with pyrazolo[4,3-e][1,2,4]triazine and pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine sulfonamides: comprehensive in vitro evaluation.Scientific reports · 2026Article
- Exon-skipping antisense oligonucleotides targeting SUMO1 and SUMO2 demonstrate chemosensitizing effects in NSCLC cells in tissue culture.Research square · 2026Article
- GSH and CES2 dual-responsive biosensor for dual-signal electron spin resonance (ESR) sensing and free radical-enhanced triple-mode therapy of hepatocellular carcinoma.Analytical and bioanalytical chemistry · 2026Article
- A novel quinine derivative as a PIM-1 kinase inhibitor induces apoptosis via mitochondrial depolarization with selective cytotoxicity in acute lymphoblastic leukemia cells.Frontiers in pharmacology · 2026Article
- Functional Characterization of VS-186B, a Novel HDAC Inhibitor with Anticancer Activity.International journal of molecular sciences · 2025Article
- Article
- Novel 4-quinolone derivative inflicted cytotoxicity via intrinsic apoptotic pathway activation on human metastatic triple-negative breast cancer cells.Bioorganic chemistry · 2025Article
- Cryopreservation of juvenile Mytilus galloprovincialis to safeguard mollusk biodiversity and support aquaculture.Scientific reports · 2025Article
- Micro-hydrogel molding-assisted fabrication of a PDMS-based microfluidic concentration-gradient generator for dynamic anticancer drug testing.RSC advances · 2025Article
- Synthesis of novel pyridazine and pyrimidine linked pyrazole derivatives as DNA ligase 1 and IV inhibitors that induce apoptosis.Chemico-biological interactions · 2025Article
- Synthesis, anticancer evaluation, and electrochemical investigation of new chiral pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine sulfonamides.Scientific reports · 2025Article
- A Multiplex Assay to Simultaneously Monitor Apoptosis and Necrosis Using the Cellaca® PLX Image Cytometer.Journal of fluorescence · 2025Article
- Article
- Anticancer Therapies Based on Oxidative Damage:Antioxidants (Basel, Switzerland) · 2024Article
- Molecular Networking-Based Metabolome, In Vitro Antidiabetic and Anti-Inflammatory Effects ofMetabolites · 2024Article
- Caffeic acid recarbonization: A green chemistry, sustainable carbon nano material platform to intervene in neurodegeneration induced by emerging contaminants.Environmental research · 2023Article
- Introduction of Androgen Receptor Targeting shRNA Inhibits Tumor Growth in Patient-Derived Prostate Cancer Xenografts.Current oncology (Toronto, Ont.) · 2023Article
- Synthesis of Novel Pyrazole-Oxindole Conjugates with Cytotoxicity in Human Cancer Cells via Apoptosis.Chemistry & biodiversity · 2023Article
- Effects of photobiomodulation by low-power lasers and LEDs on the viability, migration, and invasion of breast cancer cells.Lasers in medical science · 2023Article
- The Antiproliferative Effect of Chloroform Fraction ofPharmaceuticals (Basel, Switzerland) · 2023Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
As large quantities of novel synthetic molecules continue to be generated there is a challenge to identify therapeutic agents with cytotoxic activity. Here we introduce a Differential Nuclear Staining (DNS) assay adapted to live-cell imaging for high throughput screening (HTS) that utilizes two fluorescent DNA intercalators, Hoechst 33342 and Propidium iodide (PI). Since Hoechst can readily cross cell membranes to stain DNA of living and dead cells, it was used to label the total number of cells. In contrast, PI only enters cells with compromised plasma membranes, thus selectively labeling dead cells. The DNS assay was successfully validated by utilizing well known cytotoxic agents with fast or slow cytotoxic activities. The assay was found to be suitable for HTS with Z' factors ranging from 0.86 to 0.60 for 96 and 384-well formats, respectively. Furthermore, besides plate-to-plate reproducibility, assay quality performance was evaluated by determining ratios of signal-to-noise and signal-to-background, as well as coefficient of variation, which resulted in adequate values and validated the assay for HTS initiatives. As proof of concept, eighty structurally diverse compounds from a small molecule library were screened in a 96-well plate format using the DNS assay. Using this DNS assay, six hits with cytotoxic properties were identified and all of them were also successfully identified by using the commercially available MTS assay (CellTiter 96® Cell Proliferation Assay). In addition, the DNS and a flow cytometry assay were used to validate the activity of the cytotoxic compounds. The DNS assay was also used to generate dose-response curves and to obtain CC
Indexed as
Identifiers
27042697PMC4816492W2468689285What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.